Abstract |
Desloratadine, the active metabolite of loratadine, is a new antihistamine. Because of its anti allergy properties, desloratidine has an affinity for histamine receptors 25 to 100 times greater to those of the usual antihistamines, coupled with a capacity to inhibit the production of pro-inflammatory mediators. When evaluated in healthy volunteers, the half life of desloratadine has been estimated at 27 hours, which is comparable with a night time length of action. Many clinical studies made with patients suffering with allergic rhinitis or chronic idiopathic urticaria have shown a rapid symptom reduction, lasting 24 hours after first taking. This action was correlated with an improvement in socio-professional activity, sleep and quality of life in general. In patients suffering from allergic rhinitis, rhinomanometry showed a significant improvement in nasal congestion by desloratadine. The clinical advantages of desloratadine on antihistamines taken previously were measured in a study made on almost 48,000 patients, of whom 91% found its efficacity satisfactory. By its powerful action, coupled with an excellent tolerance profile, desloratadine represents a real therapeutic advance for allergic patients.
|
Authors | A Sabbah |
Journal | Allergie et immunologie
(Allerg Immunol (Paris))
Vol. 34
Issue 10
Pg. 377-83
(Dec 2002)
ISSN: 0397-9148 [Print] France |
Vernacular Title | Place des nouveaux antihistaminiques dans la prise en charge de l'allergie: à propos de la desloratadine. |
PMID | 12575624
(Publication Type: English Abstract, Journal Article, Review)
|
Chemical References |
- Anti-Allergic Agents
- Histamine H1 Antagonists
- Inflammation Mediators
- Recombinant Proteins
- Intercellular Adhesion Molecule-1
- Loratadine
- desloratadine
|
Topics |
- Anti-Allergic Agents
(adverse effects, pharmacology, therapeutic use)
- Double-Blind Method
- Half-Life
- Histamine H1 Antagonists
(adverse effects, pharmacology, therapeutic use)
- Histamine Release
(drug effects)
- Humans
- Hypersensitivity, Immediate
(drug therapy)
- Inflammation Mediators
(antagonists & inhibitors)
- Intercellular Adhesion Molecule-1
(drug effects)
- Liver
(metabolism)
- Loratadine
(adverse effects, analogs & derivatives, pharmacology, therapeutic use)
- Meta-Analysis as Topic
- Multicenter Studies as Topic
- Patient Acceptance of Health Care
- Randomized Controlled Trials as Topic
- Recombinant Proteins
(drug effects)
- Rhinitis, Allergic, Perennial
(drug therapy)
- Rhinitis, Allergic, Seasonal
(drug therapy)
- Safety
- Treatment Outcome
- Urticaria
(drug therapy)
|